Monoclonal anti-CGRP antibodies in post-menopausal women: a real-life study (vol 123, pg 1039, 2023)

被引：0
|
作者：
Guerzoni, Simona [1 ,2 ]
Baraldi, Carlo [3 ]
Brovia, Daria [1 ,2 ]
Cainazzo, Maria Michela [1 ,2 ]
Lo Castro, Flavia [4 ]
Pani, Luca [1 ,2 ,5 ,6 ,7 ]
机构：
[1] AOU Policlin Modena, Pharmacol & Clin Metab Toxicol Headache Ctr, Digital & Predict Med, Modena, Italy
[2] AOU Policlin Modena, Dept Specialist Med, Drug Abuse Lab Clin Pharmacol & Pharmacogen, Modena, Italy
[3] Univ Modena & Reggio Emilia, PhD Sch Neurosci, Dept Biomed Metab & Neural Sci, Modena, Italy
[4] Univ Modena & Reggio Emilia, Postgrad Sch Pharmacol, Dept Biomed Metab & Neural Sci, Modena, Italy
[5] Univ Modena & Reggio Emilia, Dept Biomed Metab & Neural Sci, Pharmacol Unit, Modena, Italy
[6] Univ Miami, Dept Psychiat & Behav Sci, Miami, FL USA
[7] VeraSci, Durham, NC USA
来源：
ACTA NEUROLOGICA BELGICA | 2023年 / 123卷 / 05期
关键词：
D O I：
10.1007/s13760-023-02340-9
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：2075 / 2075
页数：1
相关论文
共 43 条
  • [21] Real-world effectiveness of Anti-CGRP Monoclonal antibodies compared to OnabotulinumtoxinA. The RAMO study: early results
    Montisano, Danilo Antonio
    Giossi, Riccardo
    Canella, Mattia
    Altamura, Claudia
    Vernieri, Fabrizio
    Ferrarese, Carlo
    Grazzi, Licia
    CEPHALALGIA, 2023, 43 (1supp) : 228 - 229
  • [22] Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis (vol 41, pg 851, 2021)
    Drellia, Konstantina
    Kokoti, Lili
    Deligianni, Christina I.
    CEPHALALGIA, 2022, 42 (01) : 90 - 90
  • [23] Responders and super-responders to anti-CGRP mAbs: the large, prospective, multicenter, real-life, I-NEED study
    Egeo, G.
    Aurilia, C.
    Torelli, P.
    Finocchi, C.
    D'Onofrio, F.
    Messina, S.
    Colombo, B.
    Aguggia, M.
    Tasillo, M.
    Filippi, M.
    Fiorentini, G.
    Orlando, B.
    Proietti, S.
    Bonassi, S.
    Barbanti, P.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 373 - 374
  • [24] Partial and nonresponders to onabotulinumtoxinA can benefit from anti-CGRP monoclonal antibodies preventive treatment: A real-world evidence study
    Alpuente, Alicia
    Gallardo, Victor J.
    Caronna, Edoardo
    Torres-Ferrus, Marta
    Pozo-Rosich, Patricia
    EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 (07) : 2378 - 2382
  • [25] Predictors of ≥50% and ≥75% response to anti-CGRP monoclonal antibodies for migraine prevention in real life: results from a european multicenter observational study including 5818 patients
    Caronna, E.
    Gallardo, V. J.
    Alpuente, A.
    Torres-Ferrus, M.
    Huerta Villanueva, M.
    Munoz-Vendrell, A.
    Campoy Diaz, S.
    Obach Baurier, V.
    Fabregat Fabra, N.
    Gago-Viega, A.
    Sanchez Soblechero, A.
    Lozano Ros, A.
    Diaz de Teran, J.
    Membrilla Lopez, J. A.
    Rodriguez-Vico, J. S.
    Guerrero Peral, A. L.
    Garcia Azorin, D.
    Pascual, J.
    Garate, G.
    Cuadrado Godia, E.
    Dorado, L.
    Sanahuja, J.
    Echeverria Urabayen, A.
    Irimia Sieira, P.
    Sanchez del Rio, M.
    Lopez-Bravo, A.
    Alvarez Escudero, R.
    Velasco Juanes, F.
    Santos Lasaosa, S.
    Diaz Insa, S.
    Layos-Romero, A.
    Andres Lopez, A.
    Viguera Romero, J.
    Beltran Blasco, I.
    Gonzalez Oria, C.
    Zapata, S.
    Flores Pina, B.
    Fernandez Lazaro, I.
    Quintas Gutierrez, S.
    Gonzalez Martinez, A.
    Jaimes Sanchez, A.
    Garcia Gomez, A.
    Gonzalez Osorio, Y.
    Gonzalez-Quintanilla, V.
    Kortazar Zubizarreta, I.
    Manera Zorrilla-Lequerica, P.
    Miro Munoz, I.
    Guisado-Alonso, D.
    Oterino Duran, A.
    Riesco Perez, N.
    JOURNAL OF HEADACHE AND PAIN, 2024, 25
  • [26] The cognitive effects of chemotherapy in post-menopausal breast cancer patients: a controlled longitudinal study (vol 123, pg 25, 2010)
    Tager, Felice A.
    McKinley, Paula S.
    Schnabel, Freya R.
    El-Tamer, Mahmoud
    Cheung, Ying Keun K.
    Fang, Yixin
    Golden, Claire R.
    Frosch, Margery E.
    Habif, Ulya
    Mulligan, Margaret M.
    Chen, Ivy S.
    Hershman, Dawn L.
    BREAST CANCER RESEARCH AND TREATMENT, 2011, 126 (01) : 271 - 272
  • [27] Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study
    Grazzi, Licia
    Giossi, Riccardo
    Montisano, Danilo Antonio
    Canella, Mattia
    Marcosano, Marilena
    Altamura, Claudia
    Vernieri, Fabrizio
    JOURNAL OF HEADACHE AND PAIN, 2024, 25 (01):
  • [28] Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study
    Licia Grazzi
    Riccardo Giossi
    Danilo Antonio Montisano
    Mattia Canella
    Marilena Marcosano
    Claudia Altamura
    Fabrizio Vernieri
    The Journal of Headache and Pain, 25
  • [29] Efficacy, safety and tolerability of monoclonal antibodies to CGRP in patients aged >65 years: a multicenter, prospective, real-life study
    Egeo, Gabriella
    Aurilia, Cinzia
    d'Onofrio, Florindo
    Frediani, Fabio
    Messina, Roberta
    Filippi, Massimo
    Querzani, Pietro
    Autunno, Massimo
    Cevoli, Sabina
    Proietti, Stefania
    Bonassi, Stefano
    Torelli, Paola
    Barbanti, Piero
    CEPHALALGIA, 2022, 42 (1_SUPPL) : 80 - 81
  • [30] Assessment of Response to Anti-IL-5 Monoclonal Antibodies in a Tertiary Care Centre: A Real-Life Study
    Tran, S.
    L'Archeveque, J.
    Coman, I.
    Cartier, A.
    Lemiere, C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
12345